中伦助力科伦博泰在香港联交所主板上市_资讯

中伦助力科伦博泰在香港联交所主板上市

俗人俗事不俗生活

2023-07-11 20:56:17

0次

中伦助力科伦博泰在香港联交所主板上市进度条02:4000:00/02:40

2023年7月11日，四川科伦博泰生物医药股份有限公司（ “科伦博泰”，股票代码：6990.HK）完成首次公开发行境外上市外资股（H股）并在香港联合交易所有限公司（ “香港联交所”）主板成功上市。

On July 11, 2023, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (Kelun-Biotech, 06990. HK) announced its initial public offering of overseas listed foreign shares (H shares) and successful listing on the Main Board of the Stock Exchange of Hong Kong Limited.

中伦律师事务所在本次上市项目中担任联席保荐人高盛（亚洲）有限责任公司和中信证券（香港）有限公司的中国境内法律顾问，为科伦博泰本次H股发行上市及H股“全流通”项目提供了全程法律服务。中伦项目组由合伙人 陈益文、 文泽雄、刘佳负责，项目组成员包括律师姚怡丰、张逸飞、张坤、袁晓琳、臧建建、舒栎宇等。

Zhong Lun served as the PRC counsel for the joint sponsors Goldman Sachs (Asia) LLC and CITIC Securities (Hong Kong) Limited, providing legal services throughout the whole of the H shares’ issuance and full circulation. Zhong Lun partners Yiwen Chen, Zexiong Wenand Jia Liuheaded the project, and team members also included associates Yifeng Yao, Yifei Zhang, Kun Zhang, Xiaolin Yuan, Jianjian Zang, Liyu Shu, etc.

科伦博泰专注于生物技术药物及创新小分子药物的研发、生产、商业化及国际合作，围绕全球和中国未满足的临床需求，重点布局肿瘤、自身免疫、炎症和代谢等重大疾病领域，建设国际化药物研发与产业化平台，致力于成为在创新领域国际领先的企业。在生物技术药物领域，包括ADC、单抗、双抗、新靶点创新小分子药物的热点技术等，均已取得重大进展。已成功构建享誉国际的ADC研发平台OptiDC，已有4款ADC处于临床研究阶段（其中2个ADC项目分别处于注册性III期或NDA阶段），多款处于临床前研究阶段。截至2023年6月，科伦博泰拥有33个用于治疗肿瘤、自身免疫、炎症、代谢等重大疾病的创新项目，14个项目正在推进临床研究，其中多个临床试验为全球多中心研究，在包括中国和欧美等多个国家同步开展。

Kelun-Biotech is committed to the R&D, manufacturing, commercialization and international cooperation for biotechnology drugs and novel small molecule drugs in oncology, immunology and other therapeutic areas. Focusing on the unmet clinical needs of China and the rest of the world, Kelun-Biotech covers major diseases such as cancer, autoimmunity, inflammation and metabolism and has built an international platform for drug development and industrialization, with a view to becoming a leading international innovation powerhouse. Kelun-Biotech has made significant progress in the field of biotechnology drugs, with achievements including ADC, monoclonal antibody, bispecific antibody and innovative small molecule drugs for newly discovered drug targets. Kelun-Biotech have successfully built OptiDC, an internationally renowned ADC research and development platform, with four ADCs in the clinical research stage (two in phase III or NDA phase) and many in the pre-clinical research pipeline. As of June 2023, Kelun-Biotech had 33 innovative projects for the treatment of tumor, autoimmune, inflammation, metabolism and other major diseases, and 14 projects are undergoing clinical studies, many of which are global multicenter studies, conducted simultaneously in China and other countries across Europe and North America.